CD8+tumor-infiltrating lymphocytes together with CD4+tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma

Pancreas

Volumn 28, Issue 1, 2004, Pages

  Fukunaga, Akira ^a   Miyamoto, Masaki ^a   Cho, Yasushi ^a   Murakami, Soichi ^a   Kawarada, You ^a   Oshikiri, Taro ^a   Kato, Kentaro ^a   Kurokawa, Takanori ^a   Suzuoki, Masato ^a   Nakakubo, Yoshihiro ^a   Hiraoka, Kei ^a   Itoh, Tomoo ^a   Morikawa, Toshiaki ^a   Okushiba, Shunichi ^a   Kondo, Satoshi ^a   Hiroyuki, Katoh ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD4; CD8; Immunohistochemical analysis; Pancreatic adenocarcinoma; S100 protein

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CHEMISTRY; DENDRITIC CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, CD4; ANTIGENS, CD8; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 1842505346     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/00006676-200401000-00023     Document Type: Article

References (24)

1. Conlon CK, Klimstra SD, Brennan FM. Long-Term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996; 223:273-279.
2. Janes Jr., HR Niederhuber EJ, Chmiel SJ, et al. National patterns of care for pancreatic cancer. Result of survey by the Commission on Cancer. Ann Surg. 1996; 223:261-272.
3. Yoshizawa K, Nagai H, Kurihara K, et al. Long-term survival after surgical resection for pancreatic cancer. Hepatogastroenterology. 2001; 48:1153-1156.
4. Balch MC, Riley LB, Bae JY, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg. 1990; 125:200-205.
5. Ropponen MK, Eskelinen JM, Lipponen KP, et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997; 182:318-324.
6. Nguyen T, Naziruddin B, Dintzis S, et al. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes. Int J Cancer. 1999; 81:607-615.
7. Valmori D, Dutoit V, Liénard D, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000; 60:4499-4506.
8. Nukaya I, Yasumoto M, Iwasaki T, et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999; 80:92-97.
9. Duffour T-M, Chaux P, Lurquin C, et al. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol. 1999; 29:3329-3337.
10. Heukamp CL, van der Burg S, Drufhout JW, et al. Identification of three non-VNTR MUC1-derived HLA-A 0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2-Kb-transgenic mice. Int J Cancer. 2001; 91:385-392.
11. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cells nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58:3491-3494.
12. Schumacher K, Haensch W, Röefzaad C, et al. Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinoma. Cancer Res. 2001; 61:3922-3936.
13. Wang R-F. The role of MHC class 2-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001; 22:269-276.
14. Marzo LA, Kinnear FB, Lake AR, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol. 2000; 165:6047-6055.
15. Suzuki A, Masuda A, Nagata H, et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol. 2002; 196:37-43.
16. Lespagnard L, Gancberg D, Rouas G, et al. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer. 1999; 84:309-314.
17. Schröder S, Schwarz W, Rehpenning W, et al. Dendritic/Langerhans cells and prognosis in patient with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. Am J Clin Pathol. 1988; 89:295-300.
18. Tsujitani S, Furukawa T, Tamada R, et al. Langerhans cells and prognosis in patients with gastric carcinoma. Cancer. 1987; 59:501-505.
19. Ademmer K, Ebert M, Müller-Ostermeyer F, et al. Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+ CD18+ cells and CD8+ CD103+ cells by multi-epitope imaging. Clin Exp Immunol. 1997; 112:21-26.
20. Cho Y, Miyamoto M, Kato K, et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 2003; 63:1555-1559.
21. Bernstorff W, Voss M, Friechel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001; 7:925-932.
22. Huang H, Li F, Gordon RJ, et al. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Res. 2002; 62:2043-2051.
23. Bernstorff W, Spanjaard RA, Chan AK, et al. Pancreatic cancer cells can evade immuno surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery. 1999; 125:73-84.
24. Hiraoka K, Hida Y, Miyamoto M, et al. High expression of tumor-associated antigen RCAS1 in pancreas ductal adenocarcinoma in an unfavorable prognostic marker. Int J Cancer. 2002; 99:418-423.